IQVIA Holdings Inc
NYSE:IQV
IQVIA Holdings Inc
Capital Expenditures
IQVIA Holdings Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Capital Expenditures
-$602m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-22%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Capital Expenditures
-$1.4B
|
CAGR 3-Years
18%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-13%
|
|
|
Danaher Corp
NYSE:DHR
|
Capital Expenditures
-$1.4B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-9%
|
|
|
Waters Corp
NYSE:WAT
|
Capital Expenditures
-$142.5m
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Capital Expenditures
-$103.9m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-2%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Capital Expenditures
-$385m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-7%
|
|
IQVIA Holdings Inc
Glance View
In the world of healthcare, IQVIA Holdings Inc. emerges as a formidable player, seamlessly blending data analytics with the imperative of human well-being. Born from the merger of IMS Health and Quintiles in 2016, IQVIA stands at the intersection of technology and life sciences, leveraging vast amounts of health-related data to facilitate more informed decisions in drug development and patient care. The company's vast repository consists of a complex tapestry of dynamic insights from around the globe, which it transforms using sophisticated analytical tools. This technical prowess enables IQVIA to offer solutions that span clinical trials, health information services, and advanced analytics, creating substantial value for pharmaceutical and life sciences companies. At the heart of IQVIA’s revenue model lies its ability to provide strategic services that reduce the time and cost associated with the development of new pharmaceuticals. By offering an integrated suite of services from the initial phases of drug research to post-market monitoring, IQVIA assists its clients in navigating regulatory landscapes and commercializing their products effectively. Its expansive technological infrastructure does not just aid in drug development but also enhances patient engagement, creating digital pathways for more personalized healthcare solutions. Thus, IQVIA earns its keep by not only selling information but also by offering transformative insights that sharpen the competitive edge for its clients in the ever-evolving healthcare sector.
See Also
What is IQVIA Holdings Inc's Capital Expenditures?
Capital Expenditures
-602m
USD
Based on the financial report for Dec 31, 2024, IQVIA Holdings Inc's Capital Expenditures amounts to -602m USD.
What is IQVIA Holdings Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-22%
Over the last year, the Capital Expenditures growth was 7%. The average annual Capital Expenditures growth rates for IQVIA Holdings Inc have been 2% over the past three years , -1% over the past five years , and -22% over the past ten years .
You don't have any saved screeners yet